Lumipulse® G Total Tau
Immunoreaction cartridge for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of total Tau in human cerebrospinal fluid (CSF).
This CSF biomarker is intended to be used as an aid for diagnosis in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.
Product number 230312
Product number 230329
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.
Other documents
FileWhitepaper - Biomarkers for Alzheimers disease.pdf (pdf, 148.72 kb)FileFileFilePractical guide for lumbar puncture.pdf (pdf, 263.94 kb)Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Regulatory product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
Insights
Improving Clinical Diagnosis of Alzheimer’s Disease - Part 1
Many subtypes of disease exist under the umbrella of dementia with Alzheimer’s disease (AD) being the most common. AD-related dementia is...
Jan 10, 2022
By Prof. Dr. Piotr Lewczuk - Two groups of established cerebrospinal fluid (CSF) biomarkers reflect two major pathological alterations in Alzheimer's...
Jan 7, 2022
Webinar replay - Possible applications for novel CSF biomarkers
At Fujirebio we have been hosting a webinar series with leading expert speakers dedicated to current topics in the field of Alzheimer's disease...
Dec 16, 2021
-
FAQ
How does the coronavirus disease Covid-19 impact Fujirebio's operations?Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
-
Related products
-
Product inquiry
